Sentinel Node Biopsy in Endometrial Cancer

Recruiting now · Phase 3

Conditions studied: Endometrial Cancer Stage I, Sentinel Lymph Node, Surgery

In brief

Endometrial cancer (EC) is the most common gynaecological cancer. Current treatment of EC typically includes removal of the uterus and to determine the extent of the disease (removal of fallopian tubes, ovaries \& if required a lymph node dissection (surgical staging)). While lymph node dissection may be valuable to guide the need for adjuvant treatment (chemo or radiotherapy) after surgery, it has been a topic of controversy for the last 30 years. In some patients it causes morbidity, specifically lymphoedema. This recently has been replaced with sentinel node biopsy (SNB). It requires an injection of a dye into the cervix with specific equipment \& surgical dissection of the lymph node in which the dye first becomes visible. Despite this promising proposition \& similar to a lymph node dissection, the value to patients, cost effectiveness \& potential harms (e.g. lymphedema) of SNB compared to no-node dissection in EC has never been established. Aim: determine the value of SNB for patients, the healthcare system and exclude detriment to patients using a randomised approach 1:1. Stage 1 - 444 patients. Stage 2 additional 316 patients. Primary Outcome Stage 1: Proportion of participants returning to usual daily activities at 12 months from surgery using the EQ-5D which will determine when women in both groups can return to their usual activities. Primary Outcome Stage 2: Treatment non-inferiority as evaluated by disease-free survival status at 4.5 years post-surgery, as measured by the time interval between the date of randomisation and date of first recurrence. Confirmation of recurrent disease will be ascertained through clinical assessment, radiological work-up and/or histological results.

Key facts

Study ID: NCT04073706
Run by: Queensland Centre for Gynaecological Cancer
People needed: 760
Starts: 2021-01-18
Expected to finish: 2031-02-01
Last updated by the study team: 2026-01-30

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

Females, over 18 years, with histologically confirmed primary epithelial cancer of the endometrium of any cell type or uterine carcinosarcoma (mixed malignant mullerian tumour);
Clinically stage I disease (disease confined to body of uterus);
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
Signed written informed consent;
Participant must meet criteria for a laparoscopic or robotic surgical approach as determined by the treating physician (e.g. suitable for TH BSO, ability to tolerate Trendelenberg positioning)
All available clinical evidence (physical examination findings, or medical imaging such as CT, MRI or ultrasound) demonstrates no evidence of extrauterine disease
Myometrial Invasion on MRI of not more than 50%. (Only if participant is <45yo, has ONLY Grade 1 EAC and wishes to retain their ovaries).
Negative (serum or urine) pregnancy test ≤ 30 days of surgery in pre-menopausal women and women < 2 years after the onset of menopause.

You may not qualify if…

Evidence of extrauterine disease (apparent involvement of cervix, vagina, parametria, adnexa, lymph nodes, bladder, bowel or distant sites) by clinical examination and/or through medical imaging.
Enlarged retroperitoneal pelvic and/or aortic lymph nodes (>1 cm) on medical imaging;
Estimated life expectancy of less than 6 months;
Patients who have absolute contraindications for adjuvant radiotherapy and/or chemotherapy;
Patients who have previously received radiation treatment to the pelvis
Serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator);
Patient compliance and geographic proximity that do not allow adequate follow-up;
Patients with allergy to Indocyanine Green (ICG)
Patients who have had previous retroperitoneal surgery
Patients who require a retroperitoneal (pelvic +/- para-aortic) lymph node dissection (lymphadenectomy)
Other prior malignancies <5 years before inclusion, except for successfully treated keratinocyte skin cancers, or ductal carcinoma of the breast insitu
Uterine perforation during endometrial tissue sampling

Where it is running

Houston Methodist Hospital — Houston, Texas, United States (enrolling)
Centro de tratamiento e investigación sobre Cáncer Luis Carlos Sarmiento Angulo — Bogotá, Bogotá, Distrito Capital, Colombia (enrolling)
Azienda Sanitaria Universitaria Friuli Centrale (ASUFC) — Udine, Via Pozzuolo, Italy (enrolling)
National University Hospital and National University Cancer Institute — Singapore, NUH Zone B, Singapore (enrolling)
Chris O'Brien Lifehouse — Camperdown, New South Wales, Australia (enrolling)
Liverpool Hospital — Liverpool, New South Wales, Australia (enrolling)
The Wesley Hospital — Auchenflower, Queensland, Australia (enrolling)
Buderim Private Hospital — Buderim, Queensland, Australia (enrolling)
North West Private Hospital — Everton Park, Queensland, Australia (enrolling)
Royal Brisbane and Women's Hospital — Herston, Queensland, Australia (enrolling)
Mater Hospital — South Brisbane, Queensland, Australia (enrolling)
St Andrews War Memorial Hospital — Spring Hill, Queensland, Australia (enrolling)
Mercy Hospital for Women — Heidelberg, Victoria, Australia (enrolling)
Royal Women's Hospital — Parkville, Victoria, Australia (enrolling)
Hospital de Base — São José do Rio Preto, São Paulo, Brazil (enrolling)
Fundacao Antonio Prudente, AC Camargo Cancer Center — São Paulo, São Paulo, Brazil (enrolling)
Hospital Britanico — Buenos Aires, Ciudad Autónoma de Buenos Aires (caba), Argentina
Hospital Israelita Albert Einstein — São Paulo, São Paulo, Brazil
Gold Coast University Hospital — Southport, Queensland, Australia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.